探讨序贯神经阻滞治疗恶性肿瘤放化疗并发带状疱疹的临床疗效

发布时间:2018-06-23 来源: 日记大全 点击:

http://img1.qikan.com.cn/qkimages/zsyx/zsyx201812/zsyx20181248-1-l.jpg
  【摘要】 目的 探讨序贯神经阻滞治疗恶性肿瘤放化疗并发带状疱疹的临床疗效。方法 46例恶性肿瘤放化疗并发带状疱疹患者, 随机分为观察组和对照组, 各23例。对照组采用常规治疗方法, 观察组在对照组基础上采用序贯神經阻滞治疗, 比较两组患者止疱、结痂、脱痂、疼痛缓解时间及治愈情况和遗留神经痛情况。结果 观察组止疱、结痂、脱痂、疼痛缓解时间均短于对照组, 差异有统计学意义(P<0.05)。观察组治愈率86.67%明显高于对照组的63.33%, 遗留神经痛发生率6.67%明显低于对照组的33.33%, 差异有统计学意义(P<0.05)。结论 采用序贯神经阻滞治疗恶性肿瘤放化疗并发带状疱疹能够达到较好的临床效果, 临床应早发现、早治疗, 以提升治愈率, 提高患者生存质量。
  【关键词】 恶性肿瘤;放化疗;带状疱疹;早期治疗;临床观察
  DOI:10.14163/j.cnki.11-5547/r.2018.12.048
  【Abstract】 Objective To discuss the clinical efficacy of sequential nerve block in the treatment of malignant tumor with radiotherapy and chemotherapy complicated with herpes zoster. Methods A total of
  46 patients with malignant tumor with radiotherapy and chemotherapy complicated with herpes zoster were randomly divided into observation group and control group, with 23 cases in each group. The control group received conventional therapy, and the observation group received sequential nerve block on the basis of the control group. Comparison were made on herpes stopping, scarring and dislocation time, pain relief time, healing and residual neuralgia between the two groups. Results The observation group had shorter herpes stopping, scarring and dislocation time, pain relief time than the control group, and the difference was statistically significant (P<0.05). The observation group had obviously higher healing rate as 86.67% than 63.33% in the control group, and obviously lower prevalence of residual neuralgia as 6.67% than 33.33% in the control group. Their difference was statistically significant (P<0.05). Conclusion Sequential nerve block for the treatment of malignant tumor with radiotherapy and chemotherapy complicated with herpes zoster can achieve better clinical effect. Early detection and early treatment can improve the healing rate and improve the quality of life of patients.
  【Key words】 Malignant tumor; Radiotherapy and chemotherapy; Early treatment; Clinical observation
  带状疱疹是临床常见的免疫抑制类疾病, 恶性肿瘤患者均存在不同程度的细胞免疫缺陷, 加之放化疗治疗对免疫系统的破坏, 导致带状疱疹的发病率明显高于普通人群。恶性肿瘤放化疗并发带状疱疹病情严重, 疱疹分布广, 病情进展迅速, 易导致全身衰竭, 预后极差。临床的早期干预治疗是改善预后的关键, 但常规抗病毒治疗后容易遗留神经痛, 给患者带来极大的身心痛苦[1]。本研究分析恶性肿瘤放化疗并发带状疱疹的临床治疗, 旨在提升疗效, 减轻患者痛苦, 现具体报告如下。
  1 资料与方法
  1. 1 一般资料 选取2009年6月~2016年6月在本院肿瘤科治疗的46例恶性肿瘤放化疗并发带状疱疹患者, 随机分为观察组和对照组, 各23例。观察组中男12例, 女11例, 年龄47~76岁, 平均年龄(64.3±10.4)岁。对照组中男13例, 女10例, 年龄45~78岁, 平均年龄(65.2±10.9)岁。两组患者的性别、年龄等一般资料比较差异无统计学意义(P>0.05), 具有可比性。所有患者均符合恶性肿瘤放化疗并发带状疱疹诊断标准, 均采用姑息性放疗或化疗治疗, 在治疗期间或治疗后有神经痛前驱症状, 簇集性水泡沿神经分布, 以胸腰部为主;疱疹多为粟粒至绿豆大小, 簇集成群沿周围神经成带状分布, 疱疹中心有脐凹, 周围明显红晕, 部分水疱破溃、糜烂及结痂;排除有药物禁忌证、严重肝肾功能障碍者。

相关热词搜索:带状疱疹 阻滞 恶性肿瘤 化疗 并发

版权所有 蒲公英文摘 www.zhaoqt.net